Dutasteride added to anti-androgen treatment for salivary cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial studies whether adding dutasteride to standard anti-androgen therapy can shrink or slow an advanced salivary gland cancer. It is for cancers that test “androgen receptor (AR) positive,” meaning they may respond to medicines that block male-hormone signals.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced salivary gland cancer that was proven on biopsy and is not curable
- Your tumor tests “AR positive” on a special lab test (at least 1% of cancer cells)
- You are 18 years or older and can sign informed consent
- Your health status is fairly good (ECOG 0 or 1) and you can swallow well enough for study medicine
- Your blood, liver, kidney, and heart function meet lab/health limits set by the study
- Your cancer has measurable disease that can be tracked by scan results
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, Rezvilutamide, combined with standard hormone therapy for people with a rare and aggressive type of salivary gland cancer that has a high risk of coming back. The treatment aims to reduce the chance of cancer returning after surgery.
This trial tests a personalized treatment approach for recurrent or metastatic salivary gland cancer. It uses special tests on your tumor to find the best targeted therapy for your specific cancer type.
This Phase 2 study tests giving nivolumab plus docetaxel and cisplatin before surgery and radiation for certain resectable, high-grade salivary gland cancers. It aims to shrink or control the cancer early to improve outcomes after treatment.
This trial studies giving an immunotherapy drug (sintilimab) plus two chemotherapy medicines before surgery to shrink salivary gland cancer. The goal is to improve how well the cancer responds and is controlled, while still aiming for a cure through surgery.
This study tests a combination of a targeted cancer drug (antibody-drug conjugate) and focused radiation therapy for salivary gland cancers that have come back or spread after initial treatment. It may help patients whose cancer didn't respond to standard options.
This Phase 2 trial tests how well ado-trastuzumab emtansine (and compares to two standard treatment options) works for salivary gland cancers that are HER2-positive or HER2-low. It aims to see whether the study drug can control cancer better and with acceptable side effects.
Hear when a new Salivary Duct Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.